In a study of 101 patients with EGFR-mutant NSCLC, strong PD-L1 expression (TC3/IC3 ≥50% for tumor cells [TC] or ≥10% for immune cells [IC]) was significantly associated with decreased ORR and shortened PFS compared to weak (TC1-2/IC1-2: 5–49% for TC or 5–9% for IC) or negative (<5% for TC or IC) PD-L1 expression (ORR, 35.7 vs. 63.2 vs. 67.3%; p = 0.002; PFS, 3.8 vs. 6.0 vs. 9.5 months; p < 0.001), regardless of EGFR mutation (e.g., 19del or L858R) (39). This evidence concerns the gene CD274 and non-small cell lung carcinoma.